4//SEC Filing
Feinsod Matthew 4
Accession 0000950170-25-053338
CIK 0001754068other
Filed
Apr 10, 8:00 PM ET
Accepted
Apr 11, 4:52 PM ET
Size
7.9 KB
Accession
0000950170-25-053338
Insider Transaction Report
Form 4
Feinsod Matthew
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-04-10+101,000→ 101,000 totalExercise: $7.31Exp: 2035-04-09→ Common Stock (101,000 underlying) - Award
Stock Option (Right to Buy)
2025-04-10+70,551→ 70,551 totalExercise: $7.31Exp: 2035-04-09→ Common Stock (70,551 underlying)
Footnotes (2)
- [F1]The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on December 31, 2025, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
- [F2]The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
Documents
Issuer
Kalaris Therapeutics, Inc.
CIK 0001754068
Entity typeother
Related Parties
1- filerCIK 0001716950
Filing Metadata
- Form type
- 4
- Filed
- Apr 10, 8:00 PM ET
- Accepted
- Apr 11, 4:52 PM ET
- Size
- 7.9 KB